Mega Genomics Balance Sheet Health
Financial Health criteria checks 5/6
Mega Genomics has a total shareholder equity of CN¥662.6M and total debt of CN¥21.7M, which brings its debt-to-equity ratio to 3.3%. Its total assets and total liabilities are CN¥832.1M and CN¥169.4M respectively. Mega Genomics's EBIT is CN¥32.0M making its interest coverage ratio -8.2. It has cash and short-term investments of CN¥508.9M.
Key information
3.3%
Debt to equity ratio
CN¥21.69m
Debt
| Interest coverage ratio | -8.2x |
| Cash | CN¥508.93m |
| Equity | CN¥662.64m |
| Total liabilities | CN¥169.43m |
| Total assets | CN¥832.07m |
Recent financial health updates
No updates
Recent updates
Shareholders Will Be Pleased With The Quality of Mega Genomics' (HKG:6667) Earnings
Oct 03
Returns On Capital Signal Tricky Times Ahead For Mega Genomics (HKG:6667)
Aug 28Some Investors May Be Worried About Mega Genomics' (HKG:6667) Returns On Capital
May 03Calculating The Intrinsic Value Of Mega Genomics Limited (HKG:6667)
Feb 20Mega Genomics Limited's (HKG:6667) Share Price Could Signal Some Risk
Aug 12A Look At The Fair Value Of Mega Genomics Limited (HKG:6667)
Nov 07Financial Position Analysis
Short Term Liabilities: 6667's short term assets (CN¥710.9M) exceed its short term liabilities (CN¥131.0M).
Long Term Liabilities: 6667's short term assets (CN¥710.9M) exceed its long term liabilities (CN¥38.4M).
Debt to Equity History and Analysis
Debt Level: 6667 has more cash than its total debt.
Reducing Debt: Insufficient data to determine if 6667's debt to equity ratio has reduced over the past 5 years.
Debt Coverage: 6667's debt is well covered by operating cash flow (513.3%).
Interest Coverage: 6667 earns more interest than it pays, so coverage of interest payments is not a concern.